Journal of Translational Medicine (May 2018)

Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer

  • Tiphaine de Foucher,
  • Maria Sbeih,
  • Jenifer Uzan,
  • Sofiane Bendifallah,
  • Marine Lefevre,
  • Nathalie Chabbert-Buffet,
  • Selim Aractingi,
  • Catherine Uzan,
  • Issam Abd Alsalam,
  • Rana Mitri,
  • Romain H. Fontaine,
  • Emile Daraï,
  • Bassam Haddad,
  • Céline Méhats,
  • Marcos Ballester,
  • Geoffroy Canlorbe,
  • Cyril Touboul

DOI
https://doi.org/10.1186/s12967-018-1515-6
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Actual European pathological classification of early-stage endometrial cancer (EC) may show insufficient accuracy to precisely stratify recurrence risk, leading to potential over or under treatment. Micro-RNAs are post-transcriptional regulators involved in carcinogenic mechanisms, with some micro-RNA patterns of expression associated with EC characteristics and prognosis. We previously demonstrated that downregulation of micro-RNA-184 was associated with lymph node involvement in low-risk EC (LREC). The aim of this study was to evaluate whether micro-RNA signature in tumor tissues from LREC women can be correlated with the occurrence of recurrences. Methods MicroRNA expression was assessed by chip analysis and qRT-PCR in 7 formalin-fixed paraffin-embedded (FFPE) LREC primary tumors from women whose follow up showed recurrences (R+) and in 14 FFPE LREC primary tumors from women whose follow up did not show any recurrence (R−), matched for grade and age. Various statistical analyses, including enrichment analysis and a minimum p-value approach, were performed. Results The expression levels of micro-RNAs-184, -497-5p, and -196b-3p were significantly lower in R+ compared to R− women. Women with a micro-RNA-184 fold change 0.083 (n = 1; 8%), p = 0.016. Women with a micro-RNA-196 fold change 0.56 (n = 2; 13%), p = 0.001. Conclusions These findings confirm the great interest of micro-RNA-184 as a prognostic tool to improve the management of LREC women.

Keywords